Compare AbCellera Biologics Inc (ABCL) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Upwork Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Upwork Inc trades at $8.67 (market cap $1.10B). The key difference: AbCellera Biologics Inc is far larger — about 2.1× Upwork Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | UPWK | |
|---|---|---|
Market Cap | $2.35B | $1.10B |
Sector | Health | Industrials |
52-Week High | $8.12 | $22.11 |
52-Week Low | $2.78 | $7.84 |
Enterprise Value | $1.99B | $895.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
UPWK trades at $8.87, down 3.17% today, with a bullish technical signal from moving averages and ADX indicators. The company reported $787.78M revenue in 2025 with a net income margin of 14.65%, though recent quarters show earnings misses. Positive developments include a new AI partnership with Claude announced June 17, 2026, while legal investigations into securities violations pose headwinds.
The stock presents a mixed outlook: valuation ratios like P/E of 10.94 and EV/EBITDA of 5.8 suggest potential upside to the $10.67 consensus target, but earnings volatility and legal risks require caution. Growth in the gig economy supports long-term opportunity, yet investor sentiment is tempered by recent guidance cuts and shareholder lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
